Following the outbreak of the coronavirus in 2019 (SARS-CoV-19), it has been of the utmost importance to detect the virus as early as possible in order to mitigate further community spread. For this reason, a direct test was developed by utilizing DNA analysis or Polymerase Chain Reaction technology (PCR). Until recently, this test was considered the ‘gold standard’ for coronavirus testing. As demands for testing rise and access becomes more readily available, antibody immunoglobulin (Ig) tests have become increasingly popular in the scientific community as they provide rapid results regarding the presence of the virus as well as the production of antibodies. SmartChek’s testing kit provides this dual-result and has been widely used by medical staff around the world.
SmartChek Rapid IgM-IgG Dual Antibody Test for COVID-19 is used to qualitatively detect IgG and IgM antibodies of the novel coronavirus in human serum, plasma, or whole blood in vitro.
The test detects both early marker and late marker antibodies, COVID-19 IgM and IgG respectively, through a human finger-prick or venous blood samples. The test can be used for rapid screening of virus carriers that are symptomatic or asymptomatic.
Recent studies suggest that a high percentage of patients exhibit no clinical symptoms of the virus, thus screening patients is vitally important. The test is ideally suited for hospitals, clinics, and test laboratories. The test can also be effectively deployed in businesses, schools, airports, seaports, train stations, etc., giving it the potential to become a compelling force in the fight against this global threat.